BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, Gregory C, Suttle AB, Tada H, Botbyl J, Stephenson JJ. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 2013;71:1635-43. [PMID: 23636448 DOI: 10.1007/s00280-013-2164-3] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Motonaga M, Yamamoto N, Makino Y, Ando-Makihara R, Ohe Y, Takano M, Hayashi Y. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction. Cancer Chemother Pharmacol 2015;76:713-21. [PMID: 26233803 DOI: 10.1007/s00280-015-2837-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 2015;41:412-22. [PMID: 25818541 DOI: 10.1016/j.ctrv.2015.03.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
3 Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug–drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opinion on Drug Safety 2016;15:223-36. [DOI: 10.1517/14740338.2016.1128413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
4 Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert Opin Drug Metab Toxicol 2016;12:1433-44. [PMID: 27556889 DOI: 10.1080/17425255.2016.1225038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
5 Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today 2016;21:962-76. [PMID: 26995271 DOI: 10.1016/j.drudis.2016.03.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
6 Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 2013;10:4055-62. [PMID: 24044612 DOI: 10.1021/mp400403s] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 9.7] [Reference Citation Analysis]
7 Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 2014;111:1909-16. [PMID: 25349968 DOI: 10.1038/bjc.2014.503] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 13.8] [Reference Citation Analysis]
8 Palmela C, Gouveia C, Fidalgo C, Ferreira AO. Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment. BMJ Case Rep 2019;12:e228612. [PMID: 31061194 DOI: 10.1136/bcr-2018-228612] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Ferrero S, Leone Roberti Maggiore U, Aiello N, Barra F, Ditto A, Bogani G, Raspagliesi F, Lorusso D. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas. Expert Opin Drug Metab Toxicol 2017;13:881-9. [PMID: 28678537 DOI: 10.1080/17425255.2017.1351943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Mourey L, Le Louedec F, Ravaud A, Paludetto MN, Digue L, Gomez-Roca CA, Valentin T, Balardy L, Olivier P, Cabarrou B, Filleron T, Chatelut E. VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients. J Geriatr Oncol 2021;12:759-64. [PMID: 33715996 DOI: 10.1016/j.jgo.2021.02.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Shao J, Markowitz JS, Bei D, An G. Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 2014;103:3810-33. [DOI: 10.1002/jps.24113] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
12 Krens SD, Lubberman FJE, van Egmond M, Jansman FGA, Burger DM, Hamberg P, Vervenne WL, Gelderblom H, van der Graaf WTA, Desar IME, van Herpen CML, van Erp NP. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer 2021;148:2799-806. [PMID: 33428771 DOI: 10.1002/ijc.33469] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Wang YK, Yang XN, Liang WQ, Xiao Y, Zhao Q, Xiao XR, Gonzalez FJ, Li F. A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice. Xenobiotica 2019;49:655-70. [PMID: 29897827 DOI: 10.1080/00498254.2018.1489167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
14 Pisano SG, Hoffman SE, Legasto CS, McLaughlin EM, Porter K, Chen JL. Effect of Acid-Suppressive Strategies on Pazopanib Efficacy in Patients With Soft-Tissue Sarcoma. Clin Transl Sci 2019;12:529-33. [PMID: 31264782 DOI: 10.1111/cts.12648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Williams HD, Ford L, Han S, Tangso KJ, Lim S, Shackleford DM, Vodak DT, Benameur H, Pouton CW, Scammells PJ, Porter CJH. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. Mol Pharm 2018;15:5678-96. [PMID: 30376336 DOI: 10.1021/acs.molpharmaceut.8b00858] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
16 Thorn CF, Sharma MR, Altman RB, Klein TE. PharmGKB summary: pazopanib pathway, pharmacokinetics. Pharmacogenet Genomics 2017;27:307-12. [PMID: 28678138 DOI: 10.1097/FPC.0000000000000292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Morotti M, Dass PH, Harris AL, Lord S. Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. Eur J Drug Metab Pharmacokinet 2018;43:137-53. [PMID: 29019020 DOI: 10.1007/s13318-017-0442-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Ozbey AC, Combarel D, Poinsignon V, Lovera C, Saada E, Mir O, Paci A. Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC. Pharmaceuticals (Basel) 2021;14:927. [PMID: 34577627 DOI: 10.3390/ph14090927] [Reference Citation Analysis]
19 Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP. The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study). Clin Pharmacol Ther 2019;106:1076-82. [PMID: 31125423 DOI: 10.1002/cpt.1515] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
20 Gougis P, Wassermann J, Spano JP, Keynan N, Funck-Brentano C, Salem JE. Clinical pharmacology of anti-angiogenic drugs in oncology. Crit Rev Oncol Hematol 2017;119:75-93. [PMID: 28916378 DOI: 10.1016/j.critrevonc.2017.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
21 Shah HA, Fischer JH, Venepalli NK, Danciu OC, Christian S, Russell MJ, Liu LC, Zacny JP, Dudek AZ. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors. Am J Clin Oncol 2019;42:413-20. [PMID: 30973373 DOI: 10.1097/COC.0000000000000543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ruiz-Garcia A, Tan W, Li J, Haughey M, Masters J, Hibma J, Lin S. Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib. Pharmaceutics 2020;12:E330. [PMID: 32272733 DOI: 10.3390/pharmaceutics12040330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, Poncelet R, Bechter O, Albersen M, Roussel E, Baldewijns M, Tack J, Spriet I. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol 2020;76:1273-80. [PMID: 32474662 DOI: 10.1007/s00228-020-02902-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, Chatelut E, Thomas F. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res 2016;110:89-95. [PMID: 27178732 DOI: 10.1016/j.phrs.2016.05.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
25 Paludetto M, Puisset F, Le Louedec F, Allal B, Lafont T, Chatelut E, Arellano C. Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2018;154:373-83. [DOI: 10.1016/j.jpba.2018.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ouerdani A, Struemper H, Suttle AB, Ouellet D, Ribba B. Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma. CPT Pharmacometrics Syst Pharmacol 2015;4:660-8. [PMID: 26783502 DOI: 10.1002/psp4.12001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
27 Fukudo M, Tamaki G, Azumi M, Shibata H, Tandai S. Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib. Br J Clin Pharmacol 2021;87:2132-9. [PMID: 33010046 DOI: 10.1111/bcp.14580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, Pimenta JR, Machado LM, Shimba DS, Peixoto RD. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol 2021;28:783-99. [PMID: 33546228 DOI: 10.3390/curroncol28010076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lubberman FJE, van der Graaf WTA, Xu L, Cleton A, Demetri GD, Gelderblom H, van Erp NP. The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. Br J Clin Pharmacol 2019;85:2399-404. [PMID: 31290566 DOI: 10.1111/bcp.14061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP;  Dutch Pharmacology and Oncology Group (DPOG). Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86:258-273. [PMID: 31782166 DOI: 10.1111/bcp.14185] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
31 Wulkersdorfer B, Zeitlinger M, Schmid M. Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Clin Pharmacokinet 2016;55:47-77. [PMID: 26201307 DOI: 10.1007/s40262-015-0302-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
32 Hussaarts KGAM, Veerman GDM, Jansman FGA, van Gelder T, Mathijssen RHJ, van Leeuwen RWF. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol 2019;11:1758835918818347. [PMID: 30643582 DOI: 10.1177/1758835918818347] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
33 Fahmy A, Hopkins AM, Sorich MJ, Rowland A. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature. Expert Opin Drug Metab Toxicol 2021;17:803-21. [PMID: 34278936 DOI: 10.1080/17425255.2021.1943357] [Reference Citation Analysis]
34 Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinsignon V, Paci A, Mir O. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. Invest New Drugs 2017;35:247-9. [PMID: 27838867 DOI: 10.1007/s10637-016-0405-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, Park SR, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, Chen AP. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Invest New Drugs 2021. [PMID: 34180036 DOI: 10.1007/s10637-021-01138-x] [Reference Citation Analysis]
36 Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clin Pharmacokinet 2017;56:987-97. [PMID: 28185218 DOI: 10.1007/s40262-017-0510-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
37 de Jong J, Haddish-Berhane N, Hellemans P, Jiao J, Sukbuntherng J, Ouellet D. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemother Pharmacol 2018;82:299-308. [PMID: 29882017 DOI: 10.1007/s00280-018-3613-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Li J, Nickens D, Wilner K, Tan W. Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations. Oncol Ther 2021. [PMID: 34120312 DOI: 10.1007/s40487-021-00156-2] [Reference Citation Analysis]
39 Gougis P, Palmieri LJ, Funck-Brentano C, Paci A, Flippot R, Mir O, Coriat R. Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Crit Rev Oncol Hematol 2019;141:112-24. [PMID: 31276964 DOI: 10.1016/j.critrevonc.2019.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Azam C, Claraz P, Chevreau C, Vinson C, Cottura E, Mourey L, Pouessel D, Guibaud S, Pollet O, Le Goff M, Bardies C, Pelagatti V, Canonge JM, Puisset F. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. Eur J Clin Pharmacol 2020;76:579-87. [PMID: 31932871 DOI: 10.1007/s00228-020-02828-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
41 Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 2016;17:632-641. [PMID: 27068858 DOI: 10.1016/s1470-2045(16)00075-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
42 Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW. Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. Clin Pharmacokinet 2019;58:651-8. [PMID: 30367352 DOI: 10.1007/s40262-018-0719-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
43 Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev 2020;84:101966. [PMID: 32044644 DOI: 10.1016/j.ctrv.2020.101966] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
44 Yu G, Zheng QS, Wang DX, Zhou HH, Li GF. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye. Lancet Oncol 2014;15:e469-70. [PMID: 25281461 DOI: 10.1016/S1470-2045(14)70458-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
45 Gay C, Toulet D, Le Corre P. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy: Pharmacokinetic interactions of TKIs. Hematological Oncology 2017;35:259-80. [DOI: 10.1002/hon.2335] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
46 McAlister RK, Aston J, Pollack M, Du L, Koyama T, Chism DD. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma. Oncologist 2018;23:686-92. [PMID: 29487220 DOI: 10.1634/theoncologist.2017-0578] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
47 Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N, Beijnen JH, Steeghs N, Huitema ADR. Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS. Therapeutic Drug Monitoring 2018;40:230-6. [DOI: 10.1097/ftd.0000000000000479] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2017;15:724-32. [PMID: 28645482 DOI: 10.1016/j.clgc.2017.05.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
49 Milling RV, Grimm D, Krüger M, Grosse J, Kopp S, Bauer J, Infanger M, Wehland M. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension. Int J Mol Sci 2018;19:E3258. [PMID: 30347815 DOI: 10.3390/ijms19103258] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
50 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
51 Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol 2017;83:2195-204. [PMID: 28500677 DOI: 10.1111/bcp.13327] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
52 van Kalleveen MW, Walraven M, Hendriks MP. Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report. Invest New Drugs 2018;36:513-6. [PMID: 29464464 DOI: 10.1007/s10637-018-0576-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol. 2015;79:241-253. [PMID: 25125025 DOI: 10.1111/bcp.12496] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
54 Ellawatty WEA, Masuo Y, Fujita K, Yamazaki E, Ishida H, Arakawa H, Nakamichi N, Abdelwahed R, Sasaki Y, Kato Y. Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib. Drug Metab Dispos 2017;46:33-40. [DOI: 10.1124/dmd.117.076554] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
55 Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, Mcarthur GA, Dréno B, Mckenna E, Zhu Q, Mun Y, Ascierto PA. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib. European Journal of Cancer 2019;116:45-55. [DOI: 10.1016/j.ejca.2019.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM. Oral Anticancer Therapy: Management of Drug Interactions. J Oncol Pract 2019;15:81-90. [PMID: 30763198 DOI: 10.1200/JOP.18.00483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
57 Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol 2020;94:3671-722. [PMID: 33111191 DOI: 10.1007/s00204-020-02936-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
58 Liu XJ, Lu H, Sun JX, Wang SR, Mo YS, Yang XS, Shi BK. Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking. Eur J Drug Metab Pharmacokinet 2016;41:465-8. [PMID: 25737032 DOI: 10.1007/s13318-015-0252-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
59 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]